- 13 241
- 3 536 244
VJHemOnc - Video Journal of Hematology & HemOnc
United Kingdom
Registrace 11. 02. 2015
The Video Journal of Hematology & Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers.
Our goal is to expedite learning through the sharing of new data and expert opinion, and to rapidly disseminate the latest news and information to healthcare professionals, worldwide, on a range of innovative digital media - including video and blog formats.
VJHemOnc content is led by an editorial board of highly respected thought leaders with a combined expertise that spans the spectrum of hematological cancers. All content is created and published under the guidance of this board of world-leading experts.
Our goal is to expedite learning through the sharing of new data and expert opinion, and to rapidly disseminate the latest news and information to healthcare professionals, worldwide, on a range of innovative digital media - including video and blog formats.
VJHemOnc content is led by an editorial board of highly respected thought leaders with a combined expertise that spans the spectrum of hematological cancers. All content is created and published under the guidance of this board of world-leading experts.
Veno-occlusive disease as a post-transplant complication of HSCT
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the management of veno-occlusive disease (VOD) in patients treated with hematopoietic stem cell transplantation (HSCT). Prof. Mohty highlights the approval of the antithrombotic agent defibrotide and the importance of early diagnosis of VOD, which is being made possible with the new EBMT criteria. Evidence suggests VOD is more common and severe in patients treated with post-transplant cyclophosphamide (PTCy). This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
zhlédnutí: 68
Video
CAR T-cell therapy programs to improve access for patients with leukemia in Mexico
zhlédnutí 129Před 7 hodinami
Alberto Olaya-Vargas, MD, National Institute of Pediatrics, Mexico City, Mexico, discusses the challenge of accessing CAR-T therapies for pediatric leukemias in Mexico. There are plans for a collaborative program in which plasmids will be sourced from Hospital Clínic de Barcelona, followed by manufacturing CAR-T products in Mexico utilizing the CliniMacs platform. However, the absence of a unif...
Current research into post-alloSCT maintenance therapy in AML
zhlédnutí 76Před 7 hodinami
Ali Bazarbachi, MD, PhD, American University of Beirut, Beirut, Lebanon, gives an overview of current research into maintenance therapy following allogeneic stem cell transplantation (alloSCT) for acute myeloid leukemia (AML). He mentions donor lymphocyte infusion (DLI), as well as post-alloSCT azacitidine maintenance, which has been shown to be effective in several clinical trials (HOVON 156 A...
The recent expanded approval of cilta-cel into earlier lines of myeloma therapy
zhlédnutí 90Před 9 hodinami
Roberto Mina, MD, University of Turin, Turin, Italy, shares his thoughts on the recent expanded approval of ciltacabtagene autoleucel (cilta-cel) into earlier lines of treatment for multiple myeloma. This approval was based on the CARTITUDE-4 trial (NCT04181827) that showed improved survival outcomes and quality of life (QoL) as compared to standard of care (SoC) regimens. This interview took p...
Treosulfan versus busulfan-based conditioning for HSCT in transfusion-dependent thalassemia
zhlédnutí 54Před 9 hodinami
Rita Beier, MD, Hannover Medical School, Hannover, Germany, summarizes the results of a retrospective analysis evaluating the impact of treosulfan versus busulfan-based conditioning regimens in hematopoietic stem cell transplantation (HSCT) for patients with transfusion-dependent thalassemia (TDT). Interestingly, results demonstrated that the CD3 T-cell count has a significant impact on graft s...
MRD to identify those who benefit the most from FLT3 inhibition with gilteritinib in CR1 of AML
zhlédnutí 60Před 9 hodinami
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses a study (NCT02997202) investigating the efficacy of FLT3 inhibitor gilteritinib for patients with acute myeloid leukemia (AML) who are in their first complete remission (CR1) following allogeneic stem cell transplantation (alloSCT). While the study did not show overall benefit, it successfully identified pa...
The impact of donor KIR genotypes on alloSCT outcomes in AML/MDS, and the value of biobanks
zhlédnutí 63Před 9 hodinami
Johannes Schetelig, MD, MSc, University Hospital TU Dresden, Dresden, Germany, discusses a study investigating the impact of donor killer-cell immunoglobulin-like receptor (KIR) genotypes on allogeneic stem cell transplantation (alloSCT) outcomes in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The study failed to validate any of the previously proposed models that were pred...
Using MRD to guide post-alloSCT treatment decisions in AML
zhlédnutí 142Před 9 hodinami
Felicitas Thol, MD, Hannover Medical School, Hannover, Germany, discusses the value of measurable residual disease (MRD) in guiding treatment decisions post-allogeneic stem cell transplantation (alloSCT) in acute myeloid leukemia (AML). The MORPHO (NCT02997202) and SORMAIN (EudraCT 2010-018539-16) trials provide evidence for the value of MRD in guiding post-alloSCT targeted therapy with gilteri...
Targeted therapies in AML: menin, FLT3 and IDH inhibitors
zhlédnutí 107Před 9 hodinami
Felicitas Thol, MD, Hannover Medical School, Hannover, Germany, discusses advancements in targeted therapies for acute myeloid leukemia (AML). Early trial results show promise for menin inhibitors in NPM1-mutated AML. Additionally, FLT3 inhibitors like gilteritinib and IDH1/2 inhibitors such as ivosidenib and enasidenib demonstrate efficacy. Dr Thol also touches on developments in immunotherapi...
Addressing access inequality in CAR-T therapies
zhlédnutí 35Před 9 hodinami
Francesca Del Bufalo, MD, Bambino Gesù Children's Hospital, Rome, Italy, addresses the issue of access inequality in CAR-T therapies. She explores advancements in manufacturing processes aimed at expanding the availability of CAR-T therapy across more centers. Additionally, Dr Del Bufalo discusses the potential for future mixed models of manufacturing involving entities beyond pharmaceutical co...
Frontline treatment of transplant eligible patients with myeloma: current approach & future changes
zhlédnutí 90Před 9 hodinami
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the therapeutic approach used for transplant-eligible patients with multiple myeloma (MM) in the frontline setting and outlines how this may change with data from ongoing clinical trials. Findings from the PERSEUS trial (NCT03710603) suggest that the addition of daratumumab to bor...
Comparing haploSCT to other donor types in lymphoma treatment
zhlédnutí 44Před 9 hodinami
Ali Bazarbachi, MD, PhD, American University of Beirut, Beirut, Lebanon, discusses the use of haploidentical stem cell transplantation (haploSCT) in treating non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). This approach allows all transplant-eligible patients to receive treatment, with post-transplant cyclophosphamide (PTCy) as graft-versus-host disease (GvHD) prophylaxis significantly im...
Developments in the treatment of patients with FLT3-mutated AML
zhlédnutí 44Před 9 hodinami
Steven Knapper, DM, FRCPath, MRCP, BMBCh, Cardiff University, Cardiff, Wales, UK, gives an overview of the current treatment landscape for patients with FLT3-mutated acute myeloid leukemia (AML), outlining the current standard of care and how this may change with developments made in recent years. Prof. Knapper highlights that an intensive chemotherapy backbone combined with gemtuzumab ozogamic...
Treating patients with advanced-stage HL in the frontline and relapsed settings in 2024
zhlédnutí 83Před 9 hodinami
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, shares insights into the current management of patients with advanced-stage classical Hodgkin lymphoma (HL) in both the frontline and relapsed settings in the UK. In the frontline, clinicians are choosing between the ABVD and escalated BEACOPDac chemotherapy approaches, with the latter being more commonly used. Prof. Collins hopes that a more targ...
Key papers in cardio-oncology from 2023 of relevance to hematologists
zhlédnutí 78Před 16 hodinami
In this video, Alexander Lyon, MA, BM BCh, PhD, FRCP, FHFA, Royal Brompton Hospital, London, UK, outlines some of the key papers in the field of cardio-oncology from 2023 that are relevant to hematologists. These include a paper on the International Late Effects of Childhood Cancer Guideline Harmonization, a meta-analysis assessing dexrazoxane for the prevention of anthracycline cardiotoxicity,...
The ESC guidelines on cardio-oncology: incorporating the guidelines into clinical practice
zhlédnutí 70Před 16 hodinami
The ESC guidelines on cardio-oncology: incorporating the guidelines into clinical practice
The future role of AI models in hematology and the need for high-quality data sets
zhlédnutí 48Před 16 hodinami
The future role of AI models in hematology and the need for high-quality data sets
The impact of living with chronic GvHD and the nurse's perspective on treating these patients
zhlédnutí 58Před 16 hodinami
The impact of living with chronic GvHD and the nurse's perspective on treating these patients
What can clinicians do to address the impact of transfusion-dependent thalassemia on patients' QoL?
zhlédnutí 59Před 16 hodinami
What can clinicians do to address the impact of transfusion-dependent thalassemia on patients' QoL?
Using an AI model to quantify under-utilization of alloSCT for AML in the UK
zhlédnutí 41Před 16 hodinami
Using an AI model to quantify under-utilization of alloSCT for AML in the UK
Approaching treatment selection and sequencing with the recent influx of BTK inhibitors in CLL
zhlédnutí 115Před 19 hodinami
Approaching treatment selection and sequencing with the recent influx of BTK inhibitors in CLL
The future of ambulatory care in the treatment of hematological conditions and malignancies
zhlédnutí 71Před 19 hodinami
The future of ambulatory care in the treatment of hematological conditions and malignancies
Single- vs double-unit transfusion for patients with hematological disorders
zhlédnutí 32Před 19 hodinami
Single- vs double-unit transfusion for patients with hematological disorders
The novel bioactive peptide QUB-2392 shows anti-leukemic effects in leukemia cell lines
zhlédnutí 116Před 21 hodinou
The novel bioactive peptide QUB-2392 shows anti-leukemic effects in leukemia cell lines
Exciting therapeutic approaches in the AML space
zhlédnutí 118Před 21 hodinou
Exciting therapeutic approaches in the AML space
Optimizing the delivery of care for patients with hemoglobinopathies in the UK
zhlédnutí 69Před 21 hodinou
Optimizing the delivery of care for patients with hemoglobinopathies in the UK
Tackling PD1i resistance in Hodgkin lymphoma
zhlédnutí 29Před 21 hodinou
Tackling PD1i resistance in Hodgkin lymphoma
The effectiveness of ambulatory care for patients undergoing stem cell transplantation
zhlédnutí 72Před 21 hodinou
The effectiveness of ambulatory care for patients undergoing stem cell transplantation
The importance of shared-decision making when treating infants with hemophilia
zhlédnutí 56Před 21 hodinou
The importance of shared-decision making when treating infants with hemophilia
The work you do as VJHEMONC is really precious. As the daughter of an AML patient (and as a med student), your channel has taught me a lot. I hope this great channel gets the recognition it deserves soon. Greetings from Turkey ❤
Dr. Shah is the future of oncology
In other words, using mRNA to deliver DNA editing technology. Is this done through CRISPR cas-9? This is very interesting! Thank you!
I'm going to enter a clinical trial with vibecotamab in about 3-4 days. After four remissions and two stem cell transplants, I would really like to find something that gets me out of the 'medical merry-go-round. . I'm 77.
Merci Pr MOHTY
Excellent
Excellent
Excellent
Stay up-to-date with the latest in lymphoma by visiting: www.vjhemonc.com/subject/lymphoma/
For the latest updates in immuno-oncology, check out our site: 👉www.vjhemonc.com/field/immuno-oncology/
Check out the latest in rare diseases, including smoldering myeloma, rare lymphomas, rare MPNs, and more, on our site: 👉www.vjhemonc.com/subject/rare-diseases/
Discover the latest updates in ALL by visiting our site: 👉www.vjhemonc.com/subject/acute-lymphoblastic-leukemia/
Visit our site and explore the latest updates in AML with our expert interviews, roundtable discussions, features, and more: www.vjhemonc.com/subject/acute-myeloid-leukemia/
Stay updated with the latest in hematology with our feature articles! For more, visit: 👉www.vjhemonc.com/features/
Check out more transplantation content here: www.vjhemonc.com/field/transplantation/?transplantationtopic
Explore more content on lymphoma on our site: www.vjhemonc.com/subject/lymphoma/?lymphomachannel
Check out our MDS Channel to stay updated with the latest in MDS: 👉www.vjhemonc.com/subject/myelodysplastic-syndromes/
Find more content on ALL here: www.vjhemonc.com/subject/acute-lymphoblastic-leukemia/?allchannel
For the latest updates in CLL, check out our site: www.vjhemonc.com/subject/chronic-lymphocytic-leukemia/
Click here to find more content on stem cell transplantation: www.vjhemonc.com/field/transplantation/?transplantationtopic
Check out the latest in multiple myeloma on our website: www.vjhemonc.com/subject/multiple-myeloma/?myelomachannel
Check out our Multiple Myeloma Channel for all the latest in this space: 👉 www.vjhemonc.com/subject/multiple-myeloma/
Check out our website for more lymphoma content: www.vjhemonc.com/subject/lymphoma/?lymphomachannel
For the latest CAR-T & cellular therapy updates, visit our site: 👉www.vjhemonc.com/field/car-t-cellular-therapy/
For more content on stem cell transplantation check out our website: www.vjhemonc.com/field/transplantation/?transplantationtopic
For more content on MRD click here: www.vjhemonc.com/field/mrd/?mrdtopic
For more AML content check out our site 👉 www.vjhemonc.com/subject/acute-myeloid-leukemia/?amlchannel
For more CAR-T & Cellular Therapy content check out our site 👉 www.vjhemonc.com/field/car-t-cellular-therapy/
Congratulations! This is great news for AML patients.